Skip to main content

Table 2 Baseline demographics of patients included in the pharmacokinetics, safety, and clinical efficacy analyses

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Baseline demographics All patients (n = 512) Patients in clinical efficacy population (n = 76)
Conventional high loading dose regimen (n = 363) Enhanced high loading dose regimen (n = 149) P value Conventional high loading dose regimen (n = 53) Enhanced high loading dose regimen (n = 23) P value
Sex male (%) 220 (60.6%) 98 (65.8%) 0.274 33 (62.3%) 19 (82.6%) 0.109
Age (years) 64.9 ± 15.8 67.2 ± 14.2 0.127 69.1 ± 13.1 70.3 ± 14.8 0.737
Body weight (kg) 55.5 ± 11.1 55.7 ± 12.0 0.819 53.0 ± 10.3 55.0 ± 13.8 0.483
Body mass index 21.3 ± 4.0 21.5 ± 4.5 0.787 20.8 ± 3.7 20.2 ± 4.9 0.528
Serum albumin (g/dL) 2.6 ± 0.6 2.5 ± 0.6 0.174 2.5 ± 0.5 2.3 ± 0.5 0.076
Estimated glomerular filtration rate (mL/min/1.73 m2) 69.5 ± 37.7 63.0 ± 33.1 0.065 70.5 ± 38.0 62.7 ± 35.4 0.408
≥60 mL/min/1.73 m2 (Normal renal function) 211 (58.1%) 82 (55.0%) 0.520 33 (62.3%) 13 (56.5%) 0.638
Type of infection
 Bacteremia 107 (29.5%) 48 (32.2%) 0.540 15 (28.3%) 7 (30.4%) 0.851
 Infectious endocarditis 3 (0.8%) 4 (2.7%) 0.202 0 (0.0%) 0 (0.0%)
 Pneumonia (VAP in clinical efficacy population) 59 (16.3%) 21 (14.1%) 0.541 35 (66.0%) 15 (65.2%) 0.945
 Osteomyelitis and arthritis 23 (6.3%) 13 (8.7%) 0.337 6 (11.3%) 3 (13.0%) 1.000
 Central nervous system infections 0 (0.0%) 1 (0.7%) 0.291 0 (0.0%) 1 (4.3%) 0.303
 Intraabdominal infections 61 (16.8%) 24 (16.1%) 0.847
 Skin & soft tissue infections 25 (6.9%) 10 (6.7%) 0.943
 Urinary tract infections 11 (3.0%) 2 (1.3%) 0.364
 Sinusitis 2 (0.6%) 0 (0.0%) 1.000
 Mediastinitis 0 (0.0%) 0 (0.0%)
 Unknown (empiric therapy) 90 (24.8%) 41 (27.5%) 0.521
Isolated Gram-positive organisms
 MRSA 107 (43.9%) 49 (43.8%) 0.986 53 (100%) 23 (100%)
 MSSA 18 (7.4%) 9 (8.0%) 0.827
 MR-CNS 50 (20.5%) 24 (21.4%) 0.840
 MS-CNS 7 (2.9%) 1 (0.9%) 0.444
Enterococcus faecalis 16 (6.6%) 7 (6.3%) 0.913
Enterococcus faecium 41 (16.8%) 23 (20.5%) 0.394
 Other Enterococcus sp 10 (4.1%) 0 (0.0%) 0.034
 Streptococcus sp 9 (3.7%) 4 (3.6%) 1.000
 Gram-positive rod 7 (2.9%) 2 (1.8%) 0.725
  1. Age, body weight, serum albumin and estimated glomerular filtration rate are expressed as the mean ± S.D.
  2. VAP ventilator associated pneumonia, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, MR-CNS methicillin-resistant coagulase-negative Staphylococci, MS-CNS methicillin-sensitive coagulase-negative Staphylococci